Press releases

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...

Boston Scientific Corporation (NYSE: BSX) announced today that Miriam O’Sullivan has been promoted to senior vice president and chief human resources officer at Boston Scientific. Miriam...

Bolt Medical acquisition to expand cardiovascular portfolio, furthering Boston Scientific strategy to address coronary and peripheral artery disease.

Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief...

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and...

Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024. Nick Spadea-Anello, president, Electrophysiology, and Jon...

Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis...

New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024...

-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call...

Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke...

Technique may promote greater ventricular synchrony and reduce the long-term risk of heart failure associated with traditional right ventricular pacing

Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology...

Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, chairman and chief executive officer, and Dr....

Boston Scientific Corporation (NYSE: BSX) announced today the election of David Habiger to its board of directors, effective immediately. Habiger has more than 30 years of business leadership...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis...

MARLBOROUGH, Mass. and MIAMI BEACH, Fla. July 15, 2024 – Boston Scientific Corporation (NYSE: BSX) today announced the presentation of positive five-year pooled results for the Intracept™...

MARLBOROUGH, Mass., July 8, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company’s clinical data will be featured at the sixth annual American Society of Pain &...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24,...

Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it...

Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker MARLBOROUGH, Mass., May 18, 2024...